
Annual report 2025
added 04-04-2026
Koninklijke Philips N.V. EBITDA 2011-2026 | PHG
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Koninklijke Philips N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 553 M | 1.26 B | 1.37 B | 1.72 B | 1.52 B | 3.15 B | 2.27 B | 1.67 B | 3.34 B | 2.46 B | 1.19 B |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.34 B | 553 M | 1.86 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.67 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-749 M | $ 16.2 | -0.61 % | $ 175 M | ||
|
Biodesix
BDSX
|
-28.7 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
-7.8 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
-49.1 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
24.7 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
-36.3 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M | ||
|
BioNano Genomics
BNGO
|
-23.8 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
428 M | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
1.16 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
-49 M | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
-5.05 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | ||
|
Celcuity
CELC
|
-172 M | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-81.4 M | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
-398 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
381 M | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
562 M | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
4.51 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
51.1 M | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
1.59 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
1.51 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
-942 M | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
-479 M | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
3.33 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
-541 M | $ 1.34 | -0.74 % | $ 402 M | ||
|
QIAGEN N.V.
QGEN
|
660 M | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
-334 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
94.9 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
-79.8 M | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
30.2 M | $ 17.16 | -1.04 % | $ 384 M |